Bernd R. Seizinger
Board member
Pharmaceuticals
Vaccibody
Sweden
Biography
Bernd R. Seizinger, M.D., Ph.D. has been Chairman of Opsona Therapeutics Ltd. since 2009 and was Interim CEO/Executive Chairman of Opsona in 2011-2013. He was President & Chief Executive Officer of GPC Biotech and executive Vice President and Chief Scientific Officer of Genome Therapeutics Corporation in Waltham/Boston, MA, USA. From 1992-1996, he was Vice President of Oncology Drug Discovery and – in parallel – Vice President of Corporate and Academic Alliances at Bristol-Myers Squibb Pharmaceutical Research Institute in Princeton, NJ, USA. Prior to his corporate appointments, Dr. Seizinger was Associate Professor of Neuroscience at Harvard Medical School and Associate Geneticist and Director of the Molecular Neuro-Oncology Laboratory at Massachusetts General Hospital. He also held a visiting professorship at the Department of Molecular Biology at Princeton University. Dr. Seizinger has authored more than 100 publications, including a number of papers in Nature, Science and Cell, and has been the recipient of numerous scientific awards, including the Otto-Hahn-Medal of the Max-Planck-Society, the Wilson S. Stone Award for Cancer Research, and the von Recklinghausen Award by the U.S. National Neurofibromatosis Foundation. Dr. Seizinger has currently board positions in Opsona Ltd., Aprea AB, Karolinska Institute, Agennix AG and TriMod Ltd.
Research Interest
Genome Therapeutics, health care institutions, regional health authorities and life science faculties
